BrainStorm to Present at 2019 Sachs Associates European Life Sciences CEO Forum in Zurich, Switzerland
February 21 2019 - 6:00AM
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in
developing innovative autologous cellular therapies for highly
debilitating neurodegenerative diseases, announced today that Chaim
Lebovits, CEO will present at the 2019 Sachs Associates European
Life Sciences CEO Forum on February 25-26, 2019 in Zurich,
Switzerland. Mr. Lebovits will provide a corporate presentation as
well as take part at the Advances in Cell & Gene Therapies
Panel.
The 2019 Sachs Associates European Life Sciences
CEO Forum features innovative bio-pharma companies in established
and emerging global markets. The 12th annual CEO forum will address
key challenges and bring together innovative companies developing
transformative medicines uniquely positioned for growth in 2019
with a specialized emphasis on investments, partnering and alliance
management.
2019 European Life Sciences
CEO Forum Details: |
Date: |
Monday, February 25, 2019 |
|
|
Advances in Cell & Gene Therapies
Panel: |
Time: |
10:20am Central Europe Time (CET) |
Location: |
Panorama A Room at the Hilton Zurich Airport
Hotel, Switzerland |
|
|
Company Presentation: |
Presenter: |
Chaim Lebovits, CEO |
Presentation Track: |
Track A |
Location: |
Panorama C Room at the Hilton Zurich Airport
Hotel, Switzerland |
Presentation Time: |
12:45pm–1:00pm Central Europe Time (CET) |
Webcast: |
https://goo.gl/mDsZ3G |
Investor MeetingsBrainStorm
senior management will be hosting institutional investor meetings
at the 2019 European Life Sciences CEO Forum. Please use the
Investor contact information provided below to schedule a
meeting.
About NurOwn® Technology PlatformNurOwn®
technology platform (autologous MSC-NTF cells) represents a
promising investigational therapeutic approach to targeting disease
pathways important in neurodegenerative disorders. MSC-NTF cells
are produced from autologous, bone marrow-derived mesenchymal stem
cells (MSCs) that have been expanded and differentiated ex vivo.
MSCs are converted into MSC-NTF cells by growing them under
patented conditions that induce the cells to secrete high levels of
neurotrophic factors. Autologous MSC-NTF cells can effectively
deliver multiple NTFs and immunomodulatory cytokines directly to
the site of damage to elicit a desired biological effect and
ultimately slow or stabilize disease progression. BrainStorm is
currently conducting a Phase 3 pivotal trial (NCT03280056) of
autologous MSC-NTF cells for the treatment of amyotrophic lateral
sclerosis (ALS). BrainStorm recently received U.S. FDA acceptance
to initiate a Phase 2 open-label multicenter trial (NCT03799718) in
progressive Multiple Sclerosis (MS) and plans to start enrollment
in early 2019.
About BrainStorm Cell Therapeutics,
Inc. BrainStorm Cell Therapeutics Inc. is a
leading developer of innovative autologous adult stem cell
therapeutics for debilitating neurodegenerative diseases. The
Company holds the rights to clinical development and
commercialization of the NurOwn® technology platform used to
produce autologous MSC-NTF cells through an exclusive, worldwide
licensing agreement. Autologous MSC-NTF cells have received Fast
Track and Orphan Drug status designation from the U.S. Food and
Drug Administration (U.S. FDA) and the European Medicines Agency
(EMA) in ALS. BrainStorm is currently enrolling a Phase 3 pivotal
trial in ALS (NCT03280056), investigating repeat-administration of
autologous MSC-NTF cells at six sites in the U.S., supported by a
grant from the California Institute for Regenerative Medicine (CIRM
CLIN2-0989). The pivotal study is intended to support a filing for
U.S. FDA approval of autologous MSC-NTF cells in ALS. For more
information, visit BrainStorm's website at
www.brainstorm-cell.com.
Safe-Harbor Statements
Statements in this announcement other than
historical data and information constitute "forward-looking
statements" and involve risks and uncertainties that could cause
BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking
statements. Terms and phrases such as "may", "should", "would",
"could", "will", "expect", "likely", "believe", "plan", "estimate",
"predict", "potential", and similar terms and phrases are intended
to identify these forward-looking statements. The potential risks
and uncertainties include, without limitation, risks associated
with BrainStorm's limited operating history, history of losses;
minimal working capital, dependence on its license to Ramot's
technology; ability to adequately protect the technology;
dependence on key executives and on its scientific consultants;
ability to obtain required regulatory approvals; and other factors
detailed in BrainStorm's annual report on Form 10-K and quarterly
reports on Form 10-Q available at http://www.sec.gov. These factors
should be considered carefully, and readers should not place undue
reliance on BrainStorm's forward-looking statements. The
forward-looking statements contained in this press release are
based on the beliefs, expectations and opinions of management as of
the date of this press release. We do not assume any obligation to
update forward-looking statements to reflect actual results or
assumptions if circumstances or management's beliefs, expectations
or opinions should change, unless otherwise required by law.
Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee
future results, levels of activity, performance or
achievements.
CONTACTS
Media:Joseph PetrozielloBrainStorm Cell TherapeuticsPhone:
+1.215.485.6797Email: JP@brainstorm-cell.com
Investors:Michael LevitanSolebury TroutPhone:
+1.917.626.8717Email: MLevitan@troutgroup.com
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Apr 2024 to May 2024
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From May 2023 to May 2024